Tech Company Financing Transactions
BridGene Biosciences Funding Round
On 10/16/2025, BridGene Biosciences raised $28 million in Series B funding from Bayland Capital, Lapam Capital and Proxima Ventures.
Transaction Overview
Company Name
Announced On
10/16/2025
Transaction Type
Venture Equity
Amount
$28,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to advance BGC-515, a covalent TEAD inhibitor for solid tumors, through ongoing clinical development and toward Phase 2, and support the second program, expected to enter the clinic in 2027, and accelerate the development of additional programs in oncology and autoimmune diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
75 Nicholson Ln.
San Jose, CA 95134
USA
San Jose, CA 95134
USA
Phone
Website
Email Address
Overview
BridGene Biosciences is a biotechnology company focusing on discovering and developing innovative small molecules that drug high value yet previously undruggable targets, providing new paths to treat diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ping Cao
Executive Vice President
Irene Yuan
VP - Bus. Development
Linda Pullan
Browse more venture capital transactions:
Prev: 10/16/2025: Peptilogics venture capital transaction
Next: 10/16/2025: Brook venture capital transaction
Share this article
About Database of VC Transactions
We do our best to record tech company VC transactions. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs